845 related articles for article (PubMed ID: 34579759)
1. Combination strategies to maximize the benefits of cancer immunotherapy.
Zhu S; Zhang T; Zheng L; Liu H; Song W; Liu D; Li Z; Pan CX
J Hematol Oncol; 2021 Sep; 14(1):156. PubMed ID: 34579759
[TBL] [Abstract][Full Text] [Related]
2. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
3. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.
Li Z; Song W; Rubinstein M; Liu D
J Hematol Oncol; 2018 Dec; 11(1):142. PubMed ID: 30577797
[TBL] [Abstract][Full Text] [Related]
4. A Winning New Combination? Toward Clinical Application in Oncology.
Maqsood Q; Sumrin A; Iqbal M; Hussain N; Mahnoor M; Zafar Saleem M; Perveen R
Cancer Control; 2023; 30():10732748231175240. PubMed ID: 37166227
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapies and Combination Strategies for Immuno-Oncology.
Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
[TBL] [Abstract][Full Text] [Related]
6. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
7. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
[TBL] [Abstract][Full Text] [Related]
9. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
10. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.
Zheng R; Liu X; Zhang Y; Liu Y; Wang Y; Guo S; Jin X; Zhang J; Guan Y; Liu Y
Front Immunol; 2024; 15():1383978. PubMed ID: 38756774
[TBL] [Abstract][Full Text] [Related]
11. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
13. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A
Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy: it's time to better predict patients' response.
Pilard C; Ancion M; Delvenne P; Jerusalem G; Hubert P; Herfs M
Br J Cancer; 2021 Sep; 125(7):927-938. PubMed ID: 34112949
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for hepatocellular carcinoma: Current and future.
Johnston MP; Khakoo SI
World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
[TBL] [Abstract][Full Text] [Related]
19. Frontiers in cancer immunotherapy-a symposium report.
Cable J; Greenbaum B; Pe'er D; Bollard CM; Bruni S; Griffin ME; Allison JP; Wu CJ; Subudhi SK; Mardis ER; Brentjens R; Sosman JA; Cemerski S; Zavitsanou AM; Proia T; Egeblad M; Nolan G; Goswami S; Spranger S; Mackall CL
Ann N Y Acad Sci; 2021 Apr; 1489(1):30-47. PubMed ID: 33184911
[TBL] [Abstract][Full Text] [Related]
20. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.
Cilibrasi C; Papanastasopoulos P; Samuels M; Giamas G
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
